Category: 859522-19-3

On June 8, 2006, Jeppesen, Lone; Kristiansen, Marit published a patent.Formula: C7H10N2O2S2 The title of the patent was Preparation of N-heteroaromatic propionamides as glucokinase activators for treating diabetes and other diseases. And the patent contained the following:

The present invention describes 2,3-di-substituted N-heteroaromatic propionamides of Formula I ( wherein the * indicates an asym. atom; R1,R2 = H, halo, NH2, NHOH, C1-6 alkyl, perfluoro-C1-6 alkyl, etc.; R3 = C3-7 cycloalkyl and C2-4 alkyl; ring A = a monosubstituted or a disubstituted 5-6 membered heteroaromatic ring consisting of, in addition to the C=N shown, carbon atoms and 0-2 heteroatoms selected from S(O)p, 0, and N; p= 0-2) pharmaceutical compositions comprising the same; and, methods of using the same. The propionamides are glucokinase activators for the treatment II diabetes and other disorders(no data given). The preparation of I is exemplified. For example, II was prepared in 2 steps by reacting intermediate 2-amino-5-(4-methylpiperazin-1-yl)thiazole (preparation given) with 3-cyclopentyl-2-(4-methanesulfonylphenyl)propionic acid. The experimental process involved the reaction of Ethyl 2-((2-aminothiazol-5-yl)thio)acetate(cas: 859522-19-3).Formula: C7H10N2O2S2

The Article related to heteroaromatic propionamide preparation glucokinase activator diabetes treatment, metabolic disorder treatment heteroaromatic propionamide glucokinase activator, Heterocyclic Compounds (More Than One Hetero Atom): Thiazoles, Isothiazoles and other aspects.Formula: C7H10N2O2S2

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On April 25, 2013, Ogamino, Takahisa; Yamazaki, Yukiyoshi; Tanikawa, Shin; Okuda, Ayumu; Fukuda, Tomoaki; Tokuda, Okihisa; Miyake, Yoshiharu; Itoh, Shinsuke; Ishiwata, Hiroyuki published a patent.Safety of Ethyl 2-((2-aminothiazol-5-yl)thio)acetate The title of the patent was Preparation of spiroindoline compounds for activating glucokinase. And the patent contained the following:

Title compounds I [ring A = nitrogen-containing heterocyclyl; R1, R2 = independently H, halo, haloalkyl, etc.; R3 = H, (un)substituted alkyl, -COR7, etc.; R7 = H, (un)substituted alkyl, haloalkyl, etc.; R4 = H, halo, cyano, etc.; or salts or solvates thereof], useful for the treatment of diabetes, glucose intolerance, metabolic syndrome, etc., were prepared For example, reaction of 2-amino-5-chlorothiazole·HCl with 4-nitrophenyl chloroformate, treatment with tert-Bu 5-bromospiro[indoline-3,3′-pyrrolidine]-1′-carboxylate, deprotection using CF3CO2H, and acetylation afforded compound II. The invention compounds activated glucokinase activity in vitro assay, e.g., III showed 1192% activation at 1 μmol/L. The experimental process involved the reaction of Ethyl 2-((2-aminothiazol-5-yl)thio)acetate(cas: 859522-19-3).Safety of Ethyl 2-((2-aminothiazol-5-yl)thio)acetate

The Article related to spiroindoline preparation glucokinase activator, diabetes glucose intolerance metabolic syndrome treatment spiroindoline glucokinase activation, Heterocyclic Compounds (One Hetero Atom): Spiro Compounds With One Hetero Atom In Each Ring and other aspects.Safety of Ethyl 2-((2-aminothiazol-5-yl)thio)acetate

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On March 20, 2012, Murray, Anthony; Lau, Jesper; Vedsoe, Per published a patent.Synthetic Route of 859522-19-3 The title of the patent was Urea glucokinase activators. And the patent contained the following:

This application relates to novel urea glucokinase activators and use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes. Further encompassed is a pharmaceutical composition comprising a compound according to the invention and a process for preparing such. The experimental process involved the reaction of Ethyl 2-((2-aminothiazol-5-yl)thio)acetate(cas: 859522-19-3).Synthetic Route of 859522-19-3

The Article related to arylcyclopentylmethylureidothiazolylthioalkanoate preparation glucokinase activator, diabetes hyperglycemia obesity dyslipidemia treatment thiazolylthioalkanoate ureido aryl cyclopentylmethyl and other aspects.Synthetic Route of 859522-19-3

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On July 17, 2008, Murray, Anthony; Lau, Jesper; Vedsoe, Per published a patent.Quality Control of Ethyl 2-((2-aminothiazol-5-yl)thio)acetate The title of the patent was Preparation of arylureidothiazolylthioalkanoates as glucokinase activators. And the patent contained the following:

Title compounds [I; R = CH2CO2H, CH2CMe2CO2H, CMe2CO2H; R1 = substituted (heteroaryl-fused) Ph], were prepared for treatment of diabetes, hyperglycemia, obesity, syndrome X, dyslipidemia, and impaired glucose tolerance (no data). Thus, cyclopentylmethyl(2,5-difluorophenyl)amine (preparation given), Et 3-(2-aminothiazol-5-ylsulfanyl)-2,2-dimethylpropionate (preparation given), carbonyldiimidazole, and DMAP were stirred together in THF at 40-50° to give the desired urea ester, which was saponified with aqueous NaOH in THF/MeOH to give [2-[3-cyclopentylmethyl-3-(2,5-difluorophenyl)ureido]thiazol-5-ylsulfanyl]acetic acid. The experimental process involved the reaction of Ethyl 2-((2-aminothiazol-5-yl)thio)acetate(cas: 859522-19-3).Quality Control of Ethyl 2-((2-aminothiazol-5-yl)thio)acetate

The Article related to arylcyclopentylmethylureidothiazolylthioalkanoate preparation glucokinase activator, diabetes hyperglycemia obesity dyslipidemia treatment thiazolylthioalkanoate ureido aryl cyclopentylmethyl and other aspects.Quality Control of Ethyl 2-((2-aminothiazol-5-yl)thio)acetate

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On July 17, 2008, Murray, Anthony; Lau, Jesper; Vedsoe, Per; Christiansen, Lise Brown published a patent.Application of 859522-19-3 The title of the patent was Preparation of ureidothiazolylthioalkanoates as glucokinase activators. And the patent contained the following:

Title compounds were prepared for treatment of diabetes, impaired glucose tolerance, obesity, hyperglycemia, syndrome X, and dyslipidemia (no data). Thus, [2-(2-chlorobenzyloxy)ethyl]-(trans-4-methylcyclohexyl)amine TFA salt (preparation given), Et 3-(2-aminothiazol-5-ylthio)-2,2-dimethylpropionate (preparation given), carbonyldiimidazole, and DMAP were stirred together in THF for 18 h; EtOH and aqueous NaOH were added followed by heating at 75° for 5 h to give 53% 3-[2-[3-[2-(2-chlorobenzyloxy)ethyl]-3-(trans-4-methylcyclohexyl)ureido]thiazol-5-ylthio]-2,2-dimethylpropionic acid. The experimental process involved the reaction of Ethyl 2-((2-aminothiazol-5-yl)thio)acetate(cas: 859522-19-3).Application of 859522-19-3

The Article related to ureidothiazolylthioalkanoate preparation glucokinase activator, diabetes obesity hyperglycemia syndrome x treatment thiazolylthioalkanoate ureido preparation, methylcyclohexylureidothiazolylsulfanylalkanoate preparation antidiabetic and other aspects.Application of 859522-19-3

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On May 1, 2017, Xu, Jiayi; Lin, Songnian; Myers, Robert W.; Trujillo, Maria E.; Pachanski, Michele J.; Malkani, Sunita; Chen, Hsuan-shen; Chen, Zhesheng; Campbell, Brian; Eiermann, George J.; Elowe, Nadine; Farrer, Brian T.; Feng, Wen; Fu, Qinghong; Kats-Kagan, Roman; Kavana, Michael; McMasters, Daniel R.; Mitra, Kaushik; Tong, Xinchun; Xu, Libo; Zhang, Fengqi; Zhang, Rui; Addona, George H.; Berger, Joel P.; Zhang, Bei; Parmee, Emma R. published an article.Recommanded Product: 859522-19-3 The title of the article was Discovery of orally active hepatoselective glucokinase activators for treatment of Type II Diabetes Mellitus. And the article contained the following:

Systemically acting glucokinase activators (GKA) have been demonstrated in clin. trials to effectively lower blood glucose in patients with type II diabetes. However, mechanism-based hypoglycemia is a major adverse effect that limits the therapeutic potential of these agents. The authors hypothesized that the predominant mechanism leading to hypoglycemia is GKA-induced excessive insulin secretion from pancreatic β-cells at (sub-)euglycemic levels. The authors further hypothesized that restricting GK activation to hepatocytes would maintain glucose-lowering efficacy while significantly reducing hypoglycemic risk. Here the authors report the discovery of a novel series of carboxylic acid substituted GKAs based on pyridine-2-carboxamide. These GKAs exhibit preferential distribution to the liver vs. the pancreas in mice. SAR studies led to the identification of a potent and orally active hepatoselective GKA, compound I. GKA I demonstrated robust glucose lowering efficacy in high fat diet-fed mice at doses ≥10 mpk, with ≥70-fold liver:pancreas distribution, minimal effects on plasma insulin levels, and significantly reduced risk of hypoglycemia. The experimental process involved the reaction of Ethyl 2-((2-aminothiazol-5-yl)thio)acetate(cas: 859522-19-3).Recommanded Product: 859522-19-3

The Article related to glucokinase activator antidiabetic diabetes, diabetes, glucokinase, glucokinase activator (gka), glucose homeostasis, glucose metabolism, hepatoselective, hepatospecific, hexokinase iv, liver preferring, pyridine-2-carboxamide, type ii diabetes mellitus and other aspects.Recommanded Product: 859522-19-3

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica